Thirty consecutive CHF patients and 26 healthy control
subjects were evaluated for peripheral blood monocyte expression of CD14, CD16 and CD143 (ACE) by flow-cytometry, and for endothelial-derived soluble CD146 levels by ELISA.
CD14(++) CD16(+) frequency was significantly higher in CHF patients than in Controls (%, median value and IQ) (12.3, 8.7-14.8 vs 5.9, 4.7-6.9, p < 0.05, CHF vs Controls), and it increased depending on how high NYHA class was, on worsening LV ejection fraction and on circulating pro-BNP values. Furthermore, it was associated with increasing creatinine and with decreasing GFR and albumin levels. Monocyte CD143 expression was significantly elevated in CHF OICR-9429 ic50 patients as compared to Controls, and positively associated with CD14(++) CD16(+) levels. Frequencies of CD14(+)CD16(+) monocytes were significantly lower in CHF patients as compared Cediranib to Controls, and negatively correlated with levels of soluble CD146 (r = -0.529; p 0.048).
In conclusion, monocytic CD14(++)CD16(+) frequency and CD143 levels are increased and reflect disease status and progressive cardiac deterioration in CHF patients. The CD14(+)CD16(+) subset is depleted in CHF and is linked to endothelial damage in this group of patients.
Although the question of whether differences in monocyte CD14CD16 expansion are causal or whether
they represent a marker of HF progression which is potentially relevant for risk prediction remains unanswered, we believe that our data represent an important tool for exploring the role of selective inflammatory pathways in CHF progression.”
“Objective: To determine the effect of race in the risks of prematurity-related complications (PRC) after elective repeat cesarean delivery (ERCD).
Methods: The NCHS-CDC Database for the U. S. (2004-2008) was used. ERCD cases were included. Exclusion criteria were multiple gestation, trial of labor, fetal anomalies, history of diabetes and/or hypertension. PRC analyzed were: Apgar score, assisted ventilation,
intensive MEK inhibitor care admission, surfactant use, antibiotic use, seizures. Regression analysis was performed to calculate the odds ratio (OR) of these variables. Deliveries at 36-40 weeks were studied with 40 weeks as reference.
Results: Totally, 785 340 ERCDs were performed between 36 and 40 weeks. For the overall population, there was not difference in adverse outcomes between 39 and 40 weeks. The rates of PRC were significantly higher in newborns at 38 compared to 39 weeks, with similar findings in sub-analysis of whites. For African-Americans, the rate of PRC was not significantly different at 38 compared to 39 weeks.
Conclusions: We report increased rates of PRC after ERCD before 39 weeks, similar findings from smaller hospital-based studies.